Etripamil NS 70 mg

Phase 3Terminated
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Supraventricular Tachycardia

Conditions

Paroxysmal Supraventricular Tachycardia

Trial Timeline

Dec 10, 2018 โ†’ Nov 13, 2020

About Etripamil NS 70 mg

Etripamil NS 70 mg is a phase 3 stage product being developed by Medpace for Paroxysmal Supraventricular Tachycardia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03635996. Target conditions include Paroxysmal Supraventricular Tachycardia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03635996Phase 3Terminated

Competing Products

20 competing products in Paroxysmal Supraventricular Tachycardia

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
41
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
DanicopanAstraZenecaPhase 3
77
LNP023NovartisPre-clinical
23
Iptacopan (LNP023)NovartisPhase 3
77
iptacopanNovartisPhase 2
52
LNP023NovartisPhase 2
52
IptacopanNovartisPre-clinical
23
IptacopanNovartisPhase 3
77
LNP023 + Eculizumab + RavulizumabNovartisPhase 3
77
LNP023NovartisPhase 3
77
LFG316 + LNP023NovartisPhase 2
52
IptacopanNovartisPhase 3
77
CrovalimabRochePhase 3
77
ABP 959 + EculizumabAmgenPhase 3
76
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
22
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
51